Arthur Weinstein, MD
Ophthalmology · Albuquerque, NMNPI 1700871894
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $604 of the $801 with a category attached, or 75.4%. Alcon accounts for 61.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $381 and has fallen 58.6% since, to $158 in 2025. That places this record below the midpoint for ophthalmology clinicians in NM, where the typical reported total is $868.
Across 18 payments — averaging $44.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$496
- AbbVie$85
- Tearlab Corp$74
- Bausch & Lomb Americas Inc.$73
- Rxsight Inc$73
What the payments were for
- Speaking & faculty fees$688%
- Food & beverage$60475%
- Other$13016%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 10 | $496 |
| AbbVie | 3 | $85 |
| Tearlab Corp | 2 | $74 |
| Bausch & Lomb Americas Inc. | 2 | $73 |
| Rxsight Inc | 1 | $73 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$801 in reported general payments places this provider in the 45th percentile of 81 ophthalmology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 1,027 | $35,955 |
| MoxifloxacinMoxifloxacin Hcl | 377 | $8,097 |
| Ofloxacin | 569 | $7,247 |
| Diclofenac Sodium | 172 | $2,139 |
| Ketorolac Tromethamine | 15 | $587 |
| Tobramycin | 19 | $120 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Albuquerque
- Robert MelendezAlbuquerque$349K
- John PitcherAlbuquerque$307K
- Christopher RoybalAlbuquerque$51K
- Stephen ColemanAlbuquerque$12K
- Rachel DavisAlbuquerque$10K
- Ian ThompsonAlbuquerque$10K
- Paul SanchezAlbuquerque$8K
- Iuri GolubevAlbuquerque$7K
- Thomas GilletteAlbuquerque$6K
- Kenneth DownesAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.